141 related articles for article (PubMed ID: 3145171)
1. Estradiol plasma levels during long-term treatment with Norplant subdermal implants.
Croxatto HB; Díaz S; Pavez M; Brandeis A
Contraception; 1988 Oct; 38(4):465-75. PubMed ID: 3145171
[TBL] [Abstract][Full Text] [Related]
2. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
Brache V; Alvarez-Sanchez F; Faundes A; Tejada AS; Cochon L
Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
[TBL] [Abstract][Full Text] [Related]
3. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
4. Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants.
Croxatto HB; Diaz S; Pavez M; Miranda P; Brandeis A
Acta Endocrinol (Copenh); 1982 Oct; 101(2):307-11. PubMed ID: 6814139
[TBL] [Abstract][Full Text] [Related]
5. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
[TBL] [Abstract][Full Text] [Related]
6. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant use.
Alvarez F; Brache V; Tejada AS; Faúndes A
Contraception; 1986 Feb; 33(2):111-9. PubMed ID: 3084166
[TBL] [Abstract][Full Text] [Related]
7. Ovarian function during use of a levonorgestrel-releasing IUD.
Barbosa I; Bakos O; Olsson SE; Odlind V; Johansson ED
Contraception; 1990 Jul; 42(1):51-66. PubMed ID: 2117516
[TBL] [Abstract][Full Text] [Related]
8. Clinical chemistry in women treated with levonorgestrel implants (Norplant) or a TCu 200 IUD.
Croxatto HB; Diaz S; Robertson DN; Pavez M
Contraception; 1983 Mar; 27(3):281-8. PubMed ID: 6406139
[TBL] [Abstract][Full Text] [Related]
9. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses.
Alvarez F; Brache V; Faundes A; Tejada AS; Thevenin F
Contraception; 1996 Nov; 54(5):275-9. PubMed ID: 8934060
[TBL] [Abstract][Full Text] [Related]
10. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of estradiol, progesterone, and levonorgestrel are not determinants of endometrial histology or abnormal bleeding in long-term Norplant implant users.
Darney PD; Taylor RN; Klaisle C; Bottles K; Zaloudek C
Contraception; 1996 Feb; 53(2):97-100. PubMed ID: 8838486
[TBL] [Abstract][Full Text] [Related]
12. Norplant implants: the mechanism of contraceptive action.
Segal SJ; Alvarez-Sanchez F; Brache V; Faundes A; Vilja P; Tuohimaa P
Fertil Steril; 1991 Aug; 56(2):273-7. PubMed ID: 1906407
[TBL] [Abstract][Full Text] [Related]
13. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users.
Boonkasemsanti W; Reinprayoon D; Pruksananonda K; Niruttisard S; Triratanachat S; Leepipatpaiboon S; Wannakrairot P
Hum Reprod; 1996 Oct; 11 Suppl 2():115-23. PubMed ID: 8982753
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical staining of von Willebrand factor in endometrium of women during the first year of Norplant implants use.
Au CL; Affandi B; Rogers PA
Contraception; 1994 Nov; 50(5):477-89. PubMed ID: 7859456
[TBL] [Abstract][Full Text] [Related]
15. Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device.
Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T
Contraception; 1989 Feb; 39(2):195-204. PubMed ID: 2495893
[TBL] [Abstract][Full Text] [Related]
16. Immediate postpartum insertion of the norplant contraceptive device.
Molland JR; Morehead DB; Baldwin DM; Castracane VD; Lasley B; Bergquist CA
Fertil Steril; 1996 Jul; 66(1):43-8. PubMed ID: 8752609
[TBL] [Abstract][Full Text] [Related]
17. Effect of preovulatory insertion of Norplant implants over luteinizing hormone secretion and follicular development.
Brache V; Alvarez F; Faundes A; Cochon L; Thevenin F
Fertil Steril; 1996 Jun; 65(6):1110-4. PubMed ID: 8641481
[TBL] [Abstract][Full Text] [Related]
18. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices.
Sivin I; Stern J; Diaz S; Pavéz M; Alvarez F; Brache V; Mishell DR; Lacarra M; McCarthy T; Holma P
Am J Obstet Gynecol; 1992 Apr; 166(4):1208-13. PubMed ID: 1566771
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of levonorgestrel and free levonorgestrel index in women using NORPLANT implants or two covered rods (NORPLANT-2).
Olsson SE; Odlind V; Johansson ED; Nordström ML
Contraception; 1987 Mar; 35(3):215-28. PubMed ID: 3111784
[TBL] [Abstract][Full Text] [Related]
20. Endometrial angiogenic response in Norplant users.
Subakir SB; Hadisaputra W; Handoyo AE; Affandi B
Hum Reprod; 1996 Oct; 11 Suppl 2():51-5. PubMed ID: 8982746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
